Daratumumab in Primary Effusion Lymphoma Letter

In primary effusion lymphoma, a herpesvirus 8 (HHV-8)–associated neoplasm that is most common in HIV-coinfected patients, cells often express CD38. In a patient in whom systemic therapies were unsuccessful, daratumumab led to a tumor response and decreased HHV-8 levels.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 379; no. 7; pp. 689 - 690
Main Authors Shah, Nirav N, Singavi, Arun K, Harrington, Alexandra
Format Journal Article
LanguageEnglish
Published Boston Massachusetts Medical Society 16.08.2018
Subjects
Antiretroviral drugs
Bone marrow
CD38 antigen
Chemotherapy
Disclosure
Effusion
Flow cytometry
HIV
Human immunodeficiency virus
Lymphoma
Medical imaging
Medical prognosis
Multiple myeloma
Patients
Primary effusion lymphoma
Online AccessGet full text

Cover

More Information
Summary:In primary effusion lymphoma, a herpesvirus 8 (HHV-8)–associated neoplasm that is most common in HIV-coinfected patients, cells often express CD38. In a patient in whom systemic therapies were unsuccessful, daratumumab led to a tumor response and decreased HHV-8 levels.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc1806295